A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A

Launched by TAKEDA · Jun 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Susoctocog Alfa, which is an injection used to treat people with a condition known as Acquired Hemophilia A (AHA). AHA can cause unexpected bleeding, and this study aims to see if Susoctocog Alfa can help stop these bleeding events and if there are any side effects from using this treatment. The trial will involve participants in Japan who are already being treated with Susoctocog Alfa, and the doctors will monitor them for up to 90 days after their last injection to check for any side effects and to see how well the treatment is working.

To participate in this study, you need to have been diagnosed with Acquired Hemophilia A and be receiving treatment with Susoctocog Alfa. There are no specific exclusions, meaning that if you meet the criteria, you can likely join. If you take part in this trial, your treatment will follow the usual practices at your clinic, and you'll have regular check-ins with the doctors to ensure your safety and to gather important information about how the medication affects you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - All participants with Acquired Haemophilia A, treated with Susoctocog Alfa (Genetical Recombination).
• Exclusion Criteria:
• • - None